199 related articles for article (PubMed ID: 1173367)
1. Dissociation of serum LATS activity and hyperfunction and autonomy of the thyroid gland in Graves' disease.
Hennemann G; Dolman A; Docter R; De Reus A; Van Zijl J
J Clin Endocrinol Metab; 1975 Jun; 40(6):935-41. PubMed ID: 1173367
[TBL] [Abstract][Full Text] [Related]
2. Correlation between long-acting thyroid stimulator protector level and thyroid 131-I uptake in thyrotoxicosis.
Adams DD; Kennedy TH; Stewart RD
Br Med J; 1974 Apr; 2(5912):199-201. PubMed ID: 4406686
[TBL] [Abstract][Full Text] [Related]
3. Validation of cytochemical section bioassay for thyroid-stimulating immunoglobulins in treated and untreated Graves' disease.
Prentice MG; Alaghband-Zadeh J; Wise PH
J Immunoassay; 1984; 5(3-4):275-90. PubMed ID: 6549396
[TBL] [Abstract][Full Text] [Related]
4. Influence of the long-acting thyroid stimulator (LATS) on radioiodine-labelled thyroxine and triiodothyronine in the thyroid of mice.
Emrich D; von Toll-Jürgens KH; zur Mühlen A Von
Endocrinology; 1970 Sep; 87(3):632-6. PubMed ID: 5424582
[No Abstract] [Full Text] [Related]
5. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease.
Takamatsu J; Hosoya T; Naito N; Yoshimura H; Kohno Y; Tarutani O; Kuma K; Sakane S; Takeda K; Mozai T
J Clin Endocrinol Metab; 1988 Jan; 66(1):147-52. PubMed ID: 3335601
[TBL] [Abstract][Full Text] [Related]
6. The effect of radioablation of the thyroid gland in Graves' disease with high levels of long-acting thyroid stimulator (LATS).
Volpé R; Desbarats-Schonbaum ML; Schonbaum E; Row VV; Ezrin C
Am J Med; 1969 Feb; 46(2):217-26. PubMed ID: 5818477
[No Abstract] [Full Text] [Related]
7. The prediction of relapse after drug treatment of Graves' disease by assay of long acting thyroid stimulator-protector (LATS-P).
Hardisty CA; Hanford L; Munro DS
Clin Endocrinol (Oxf); 1981 May; 14(5):509-17. PubMed ID: 6895487
[TBL] [Abstract][Full Text] [Related]
8. Thyrotrophin binding inhibiting immunoglobulins in Graves' disease before, during and after antithyroid therapy, and its relation to long-acting thyroid stimulator.
Docter R; Bos G; Visser TJ; Hennemann G
Clin Endocrinol (Oxf); 1980 Feb; 12(2):143-53. PubMed ID: 6105023
[TBL] [Abstract][Full Text] [Related]
9. LATS protector and abnormal thyroid stimulation in diffuse toxic goitre.
Stewart RD
N Z Med J; 1975 Jan; 81(531):24. PubMed ID: 1055311
[No Abstract] [Full Text] [Related]
10. Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto's thyroiditis.
Endo K; Kasagi K; Konishi J; Ikekubo K; Okuno T; Takeda Y; Mori T; Torizuka K
J Clin Endocrinol Metab; 1978 May; 46(5):734-9. PubMed ID: 45421
[TBL] [Abstract][Full Text] [Related]
11. Dissociation of serum LATS content and thyroid suppressibility during treatment of hyperthyroidism.
Chopra IJ; Solomon DH; Johnson DE; Chopra U; Fischer DA
J Clin Endocrinol Metab; 1970 Apr; 30(4):524-8. PubMed ID: 5435290
[No Abstract] [Full Text] [Related]
12. Thyroidal triiodothyronine and thyroxine in Graves' disease: correlation with presurgical treatment, thyroid status, and iodine content.
Larsen PR
J Clin Endocrinol Metab; 1975 Dec; 41(06):1098-104. PubMed ID: 54364
[TBL] [Abstract][Full Text] [Related]
13. [Development of serum LATS activity in some cases of Basedow's disease treated with corticoids or immunodepressants].
Linquette M; Fossati P; Decoulx M; Hubschman B
Ann Endocrinol (Paris); 1968; 29(6):731-9. PubMed ID: 5757239
[No Abstract] [Full Text] [Related]
14. Serum long acting thyroid stimulator (LATS) and LATS-protector (LATS-P) in Graves' disease associated with localized myxedema.
Hardisty CA; Fowles A; Munro DS
J Endocrinol Invest; 1984 Apr; 7(2):151-5. PubMed ID: 6547156
[TBL] [Abstract][Full Text] [Related]
15. Interaction of the mouse thyrotrophin receptor with thyrotrophin binding inhibitor immunoglobulins.
Luttrell BM
J Endocrinol; 1983 Mar; 96(3):481-8. PubMed ID: 6131925
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis of Graves' ophthalmopathy without hyperthyroidism: long-acting thyroid stimulator (LATS) determination as laboratory adjunct.
Gharib H; Mayberry WE
Mayo Clin Proc; 1970 Jun; 45(6):444-9. PubMed ID: 4193249
[No Abstract] [Full Text] [Related]
17. [Long term effects of the treatment of the Graves' disease by 4 different therapeutics (author's transl)].
Mornex R; Quintana J; Chavrier B
Ann Endocrinol (Paris); 1977; 38(4):273-82. PubMed ID: 578399
[TBL] [Abstract][Full Text] [Related]
18. The use of the E-rosette as a test for remission in Graves' disease treated with antithyroid drugs.
Farid NR; Munro R; Row VV; Volpé R
Clin Endocrinol (Oxf); 1974 Jan; 3(1):55-61. PubMed ID: 4407296
[No Abstract] [Full Text] [Related]
19. Transient thyrotoxicosis in an infant delivered to a long-acting thyroid stimulator (LATS)- and LATS protector-negative, thyroid-stimulating antibody-positive woman with Hashimoto's thyroiditis.
Hoffman WH; Sahasrananan P; Ferandos SS; Burek CL; Rose NR
J Clin Endocrinol Metab; 1982 Feb; 54(2):354-6. PubMed ID: 6119322
[TBL] [Abstract][Full Text] [Related]
20. Prediction of outcome in Graves' disease after carbimazole treatment.
Weetman AP; Ratanachaiyavong S; Middleton GW; Love W; John R; Owen GM; Darke C; Lazarus JH; Hall R; McGregor AM
Q J Med; 1986 Apr; 59(228):409-19. PubMed ID: 2875484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
